New CRO system-level expansion elevates data stewardship and enables organizations to gain more insight with less oversight

Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals, will launch Signals Synergy^TM, a software solution designed to drive greater collaboration, project management, and data exchange between pharmaceutical and biotechnology sponsors with their external contract partners.

Addressing the challenge of relying on email or file-sharing platforms to report complex scientific findings, Signals Synergy expands its Signals Notebook and Signals Research Suite offerings to serve as a data steward and project management layer between sponsors and contract partners. These capabilities enable Signals Synergy to streamline processes, enhance sustainability, and reduce the errors and delays commonly associated with conventional systems.

Kevin Willoe, SVP and general manager of Revvity Signals Software, emphasized the transformative potential of Signals Synergy: "We understand the importance of collaboration and data integrity for our pharma and biotech customers as they work with global contract partners to conduct complex experiments and communicate results. We see Signals Synergy as a driver of digital innovation, merging scientific project management with efficient data sharing into one seamless platform. With Signals Synergy, Revvity Signals is proud to offer the most comprehensive solution on the market, poised to accelerate the pace of drug innovation like never before."

Revvity Signals Software will officially introduce Signals Synergy at the Bio-IT World Conference & Expo, April 15-17, in Boston, Massachusetts.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240415189154/en/